Cholinergic agonists increase the activity of the parasympathetic nervous system and of cholinergic synapses throughout the autonomic nervous system (ANS). They fall into two mechanistic categories: direct-acting agonists that bind and activate muscarinic acetylcholine receptors (mAChRs) or nicotinic acetylcholine receptors (nAChRs) directly, and indirect-acting agents (acetylcholinesterase [AChE] inhibitors) that increase the synaptic concentration and duration of action of endogenous acetylcholine (ACh) by blocking its enzymatic degradation.
Choline Esters. The choline esters are the oldest direct-acting cholinergic agonists and represent synthetic analogs of ACh designed to resist rapid hydrolysis. Acetylcholine itself has no therapeutic applications because it is hydrolyzed within seconds in plasma and tissues by both AChE and butyrylcholinesterase (BuChE), making sustained receptor activation impossible. Methacholine (acetyl-beta-methylcholine) is resistant to BuChE and hydrolyzed more slowly by AChE than ACh; it has high muscarinic selectivity and is used clinically in the methacholine challenge test (bronchoprovocation testing) to diagnose airway hyperresponsiveness in suspected asthma. Carbachol (carbamylcholine) is resistant to both AChE and BuChE and activates both muscarinic and nicotinic receptors. It is used topically in the eye to reduce intraocular pressure (IOP) in glaucoma and to produce miosis during ophthalmic procedures; systemic absorption must be avoided because ganglionic nicotinic (NN) receptor stimulation combined with muscarinic activation would produce uncontrolled autonomic effects. Bethanechol is a quaternary carbamate ester that selectively activates muscarinic receptors without appreciable nicotinic activity and is resistant to cholinesterase hydrolysis. Its primary clinical uses are to stimulate detrusor contraction in urinary retention (particularly postoperative or postpartum neurogenic bladder) and to stimulate gastric and intestinal motility in paralytic ileus. It does not cross the blood-brain barrier (BBB) and therefore produces only peripheral muscarinic effects.1
Alkaloid Muscarinic Agonists. Pilocarpine and muscarine are naturally occurring alkaloids that activate muscarinic receptors. Pilocarpine, a tertiary amine derived from Pilocarpus jaborandi leaves, crosses cell membranes and is used primarily in ophthalmology: applied topically, it produces miosis (iris sphincter M3 activation) and ciliary muscle contraction (accommodation for near vision), which together open the trabecular meshwork and Schlemm's canal drainage channels, reducing IOP in angle-closure and open-angle glaucoma. Pilocarpine is also used orally in Sjögren syndrome and as a radiation-induced xerostomia (dry mouth) treatment to stimulate salivary gland M3 receptor-mediated secretion. Cevimeline is a quinuclidine derivative with higher selectivity for salivary and lacrimal gland M3 receptors relative to cardiac muscarinic M2 (M2) receptors, offering a therapeutic advantage over pilocarpine in patients in whom cardiac muscarinic activation (bradycardia) must be minimized. Muscarine has no clinical use; it is primarily significant as a toxicological agent found in certain mushroom species (Inocybe and Clitocybe spp.) and as the compound from which the muscarinic receptor class derives its name. Muscarine poisoning produces the cholinergic toxidrome: salivation, lacrimation, urination, defecation, gastrointestinal (GI) cramping, and emesis (SLUDGE), treated with atropine.15
AChE Inhibitors as Indirect Cholinergic Agonists. Acetylcholinesterase inhibitors (AChEIs) do not directly activate cholinergic receptors but instead amplify the action of endogenous ACh at all cholinergic synapses by preventing its hydrolysis. The pharmacological consequences depend entirely on where endogenous ACh is being released: at muscarinic neuroeffector junctions, AChEIs produce the expected parasympathomimetic effects (bradycardia, bronchoconstriction, increased GI motility, miosis); at the neuromuscular junction (NMJ), they increase ACh concentration and overcome the competitive block of non-depolarizing neuromuscular blockers (NMBs); at autonomic ganglia, they enhance ganglionic transmission; and in the central nervous system (CNS), they increase cholinergic tone in the cortex and hippocampus.
The reversible AChEIs used for myasthenia gravis (MG) treatment (neostigmine, pyridostigmine) are quaternary ammonium compounds that cannot cross the BBB, confining their effects to peripheral cholinergic synapses. Neostigmine is preferred for acute MG exacerbations and for reversal of non-depolarizing neuromuscular blockade (NMB) because of its faster onset, while pyridostigmine is preferred for chronic MG maintenance because of its longer duration (approximately 3 to 6 hours). Edrophonium, with its very short duration (minutes), is used for the Tensilon test. The longer-acting CNS-penetrant AChEIs (donepezil, rivastigmine, galantamine) used in Alzheimer disease increase cortical and hippocampal ACh, modestly improving cognitive function and slowing functional decline, but do not alter disease progression. Rivastigmine also inhibits BuChE in addition to AChE, providing additional cholinomimetic activity at sites where BuChE is expressed.13
Varenicline and Nicotinic Agonists. Varenicline is a selective partial agonist at the alpha4-beta2 nicotinic acetylcholine receptor (nAChR) subtype that mediates nicotine dependence in the CNS. As a partial agonist, it produces submaximal stimulation of the receptor, reducing nicotine craving and withdrawal symptoms, while simultaneously blocking the full agonist effect of inhaled nicotine if the patient smokes during treatment. Varenicline has been shown in randomized controlled trials to substantially increase rates of sustained abstinence from smoking at 1 year compared to placebo and bupropion. Its primary adverse effects include nausea (the most common reason for dose reduction or discontinuation), vivid dreams, and rare neuropsychiatric symptoms; a black box warning regarding mood changes was removed from its labeling in 2016 after large randomized trials did not confirm a clinically meaningful increase in neuropsychiatric adverse events compared to placebo in the target population. Nicotine replacement therapy (NRT) in various formulations (patch, gum, lozenge, inhaler, nasal spray) provides a partial substitute for inhaled nicotine at a lower and more controlled rate, reducing withdrawal symptoms while allowing behavioral modification without the carcinogens of tobacco smoke.4
Bethanechol and pilocarpine (and all direct muscarinic agonists) are contraindicated in: asthma or COPD (bronchoconstriction via M3 in airways); peptic ulcer disease (increased gastric acid secretion via M1 and M3); bowel or bladder obstruction (contraction against a mechanical obstruction risks perforation or rupture); hyperthyroidism (bradycardia may be poorly tolerated); coronary artery disease with angina (excessive bradycardia or reduced coronary perfusion). AChEIs at high doses can produce a cholinergic crisis: excessive muscarinic stimulation (SLUDGE, bronchospasm, bradycardia) plus nicotinic overstimulation (fasciculations, weakness, paralysis) that mimics organophosphate toxicity. Treated with atropine for muscarinic effects and pralidoxime if due to organophosphate AChEI; supportive care and ventilatory support for paralysis.
Cholinergic antagonists block the postsynaptic effects of ACh at muscarinic or nicotinic receptors. The antimuscarinics (muscarinic receptor antagonists) form the clinically most important group, with applications spanning cardiology, pulmonology, urology, ophthalmology, gastroenterology, and neurology. Ganglionic blockers occupy a narrower niche, exploiting the nicotinic ganglionic (NN) receptor at autonomic ganglia to produce global autonomic paralysis.
Atropine: The Prototype Antimuscarinic. Atropine is a naturally occurring tertiary amine alkaloid derived from Atropa belladonna and Datura stramonium. As a competitive antagonist at all five mAChR subtypes, atropine produces dose-dependent, organ-specific effects that reflect the baseline parasympathetic tone of each tissue. At low doses (0.5 mg), the paradoxical initial slowing of heart rate observed in some patients is attributed to blockade of presynaptic muscarinic M1 (M1) receptors in the cardiac vagal centers of the brainstem, transiently increasing vagal outflow before the predominant muscarinic M2 (M2) blockade effect emerges. At higher doses (1 to 2 mg), M2 receptor blockade at the sinoatrial (SA) node produces tachycardia, the most consistent cardiovascular effect. Atropine reduces salivary, lacrimal, bronchial, and sweat gland secretions (M3 blockade), producing dry mouth, dry eyes, anhidrosis, and reduced bronchial secretions. The anhidrosis without sympathetic vasodilation impairs heat dissipation and may cause hyperthermia, particularly in children or high-temperature environments. Atropine reduces gastrointestinal (GI) motility (M3 and M2 blockade), causes urinary retention (M3 blockade at detrusor), produces mydriasis and cycloplegia (M3 blockade at iris sphincter and ciliary muscle).
At higher doses, atropine crosses the blood-brain barrier (BBB) to produce central nervous system (CNS) effects: excitement, delirium, hallucinations, and in severe toxicity, coma. The CNS toxicity of atropine is treated with physostigmine, the only AChEI that crosses the BBB and can therefore reverse central antimuscarinic effects.5
Organ-Selective Antimuscarinic Agents. The adverse effects of non-selective antimuscarinic agents (dry mouth, constipation, urinary retention, cognitive impairment in elderly patients) have driven development of agents with improved organ selectivity. Ipratropium bromide and tiotropium bromide are quaternary amines that do not cross the BBB and are given by inhalation, producing bronchodilation through M3 blockade in the airways with negligible systemic anticholinergic effects; tiotropium has longer binding to M3 and M1 receptors relative to M2, giving it a longer duration of action and less M2-mediated tachycardia than ipratropium. The urinary bladder antimuscarinics (oxybutynin, tolterodine, solifenacin, darifenacin, trospium, fesoterodine) are M3 and M2 antagonists that reduce detrusor overactivity; darifenacin and solifenacin have relative M3 selectivity, reducing systemic side effects. Oxybutynin crosses the BBB and produces cognitive impairment, particularly in elderly patients; trospium (quaternary amine) does not cross the BBB and is preferred in patients at risk of anticholinergic cognitive effects. Scopolamine (hyoscine) is a tertiary amine with high CNS penetrance used for motion sickness prevention (transdermal patch) and as a preanesthetic agent; it produces sedation and amnesia in addition to peripheral muscarinic blockade. Glycopyrrolate is a quaternary ammonium compound used for intraoperative bradycardia and perioperative antisecretory effects; its inability to cross the BBB makes it preferred over atropine for drying secretions without CNS side effects.5
Antimuscarinics in Specific Clinical Contexts. In the perioperative setting, antimuscarinics serve as antisialagogues (reducing airway secretions before intubation), as reversal agents for bradycardia produced by neostigmine-based neuromuscular blockade (NMB) reversal (neostigmine increases ACh at cardiac M2 receptors, requiring concurrent atropine or glycopyrrolate), and as treatment for intraoperative vagal reflexes during airway manipulation. In organophosphate (OP) poisoning, atropine is the cornerstone of treatment, targeting muscarinic excess (SLUDGE [salivation, lacrimation, urination, defecation, GI cramping, emesis], bronchospasm, bradycardia, hypersecretion); the dose is titrated to drying of secretions rather than to heart rate, as the goal is reversal of bronchoconstriction and hypersecretion, not tachycardia. In Parkinson disease, the anticholinergics benztropine and trihexyphenidyl reduce tremor by blocking muscarinic M1 (M1) and M4 (M4) receptors in the striatum, restoring the balance between cholinergic and dopaminergic tone disrupted by dopaminergic neuron loss; they are less effective for bradykinesia and rigidity and are poorly tolerated in older patients due to anticholinergic cognitive effects. Atropine eye drops or ointment are used for uveitis (cycloplegia prevents painful ciliary spasm) and for treatment of amblyopia in children by deliberately blurring vision in the stronger eye to force use of the amblyopic eye.5
Ganglionic Blocking Drugs. Ganglionic blockers (also called ganglioplegics) block transmission at autonomic ganglia by antagonizing NN nicotinic receptors (predominantly alpha3-beta4 subunit composition) that mediate preganglionic-to-postganglionic synaptic transmission in both the sympathetic and parasympathetic nervous systems simultaneously. Because all autonomic ganglia are blocked regardless of division, the net organ effects are determined by which division carries the dominant resting tone to each organ. Heart: dominant vagal (parasympathetic) tone → ganglionic blockade removes vagal dominance → tachycardia and reduced cardiac output. Blood vessels: dominant sympathetic tone → blockade removes vasoconstrictor tone → vasodilation and profound orthostatic hypotension. GI tract: dominant parasympathetic tone → blockade reduces motility and secretion → constipation and dry mouth. Bladder: dominant parasympathetic tone → urinary retention. Eye: dual innervation with parasympathetic dominant for pupil constriction → mydriasis. Trimethaphan is the only ganglionic blocker currently in clinical use, retained for emergency management of hypertensive urgency in aortic dissection, where simultaneous reduction in blood pressure and myocardial contractility (dP/dt) limits aortic wall stress. Mecamylamine, an older oral ganglionic blocker, is now used experimentally for research into autonomic ganglionic physiology and has been investigated as an adjunct smoking cessation treatment due to its CNS nicotinic receptor-blocking properties.56
The antimuscarinic toxidrome results from excess muscarinic blockade, whether from intentional overdose (antihistamines, TCAs, antipsychotics, scopolamine), accidental ingestion (jimsonweed, deadly nightshade), or therapeutic excess. Clinical features: tachycardia, flushing, hyperthermia (anhidrosis without cooling), dry skin and mucous membranes, mydriasis, urinary retention, decreased bowel sounds, and CNS effects (delirium, agitation, hallucinations, coma). Memory aid: "hot as a hare, blind as a bat, dry as a bone, red as a beet, mad as a hatter." Management: physostigmine 1 to 2 mg IV (slowly) reverses both peripheral and central antimuscarinic effects; contraindicated in TCA overdose (physostigmine may worsen cardiac conduction abnormalities from TCA sodium channel blockade); benzodiazepines for agitation; urinary catheterization for retention; cooling measures for hyperthermia.
Adrenergic agonists (sympathomimetics) activate one or more adrenergic receptor (AR) subtypes to produce sympathomimetic effects. They are classified by mechanism of action (direct receptor activation versus indirect release of norepinephrine [NE] from sympathetic terminals versus a combination of both), by receptor selectivity (alpha-1, alpha-2, beta-1, beta-2, beta-3, or combinations), and by their origin (endogenous catecholamines or synthetic analogs). Understanding the receptor selectivity profile of each agent allows prediction of its cardiovascular, respiratory, and metabolic effects without memorization of individual drug properties.
Endogenous Catecholamines: Epinephrine, NE, and Dopamine. Epinephrine (adrenaline) is the endogenous ligand of the adrenal medulla, with essentially equal affinity for alpha-1, alpha-2, beta-1, and beta-2 ARs. At low doses, the high sensitivity of beta-2 ARs in skeletal muscle vasculature and bronchial smooth muscle produces vasodilation and bronchodilation, lowering diastolic blood pressure (DBP) while beta-1 stimulation increases heart rate and cardiac output, raising systolic blood pressure (SBP) and widening pulse pressure. At higher doses, alpha-1 vasoconstriction dominates, raising both SBP and DBP. Epinephrine is the drug of choice in anaphylaxis (reverses laryngeal edema via alpha-1, increases cardiac output via beta-1, and reverses bronchoconstriction via beta-2 simultaneously), the first drug given in cardiac arrest (increases coronary and cerebral perfusion pressure during CPR via alpha-1), and a component of local anesthetic solutions (causes local vasoconstriction, prolonging anesthetic duration and reducing systemic absorption). Norepinephrine (noradrenaline) has high affinity for alpha-1, alpha-2, and beta-1 ARs with negligible beta-2 activity. Its net cardiovascular effect is increased SBP and DBP from alpha-1 vasoconstriction, accompanied by reflex bradycardia from baroreceptor activation; cardiac output may fall or remain unchanged despite increased contractility because of the increased afterload. NE is the first-line vasopressor in septic shock (distributive shock from vasodilation) per current international guidelines.78
Dopamine Infusion Rate-Response. Dopamine at low infusion rates (1 to 3 mcg/kg/min) activates dopamine D1 (D1) receptors in renal and mesenteric vasculature; at intermediate rates (3 to 10 mcg/kg/min) beta-1 AR predominates, increasing cardiac output; at high rates (>10 mcg/kg/min) alpha-1 vasoconstriction dominates. Dopamine is now rarely preferred over NE in septic shock because of higher rates of tachyarrhythmia.28
Selective Beta-1 Agonists. Dobutamine is a synthetic catecholamine with predominant beta-1 AR agonism and weaker beta-2 and alpha-1 activity. Its net cardiovascular effect is increased cardiac output (positive inotropy and moderate chronotropy) with decreased SVR (systemic vascular resistance; from beta-2 vasodilation partially offsetting any alpha-1 vasoconstriction), making it useful in cardiogenic shock and acute decompensated heart failure where both cardiac output and SVR are problematic. The increase in cardiac output without a rise in mean arterial pressure (MAP) distinguishes dobutamine from vasopressors; it does not treat hypotension from vasodilation, where NE is appropriate. Dobutamine stress echocardiography (DSE) exploits its inotropic and chronotropic properties to unmask inducible wall motion abnormalities in coronary artery disease (CAD) without exercise. Isoproterenol is a non-selective beta-1 and beta-2 agonist with no alpha AR activity; it increases heart rate (useful in hemodynamically significant bradycardia unresponsive to atropine as a temporizing measure before pacing) and produces vasodilation, making it unsuitable as a vasopressor. It is also used to facilitate electrophysiology (EP) studies and to stimulate heart rate in transplanted denervated hearts.7
Selective Beta-2 Agonists. The selective beta-2 agonists are primarily used for bronchodilation in asthma and chronic obstructive pulmonary disease (COPD). Short-acting beta-2 agonists (SABAs; albuterol/salbutamol, levalbuterol, terbutaline) provide rapid onset bronchodilation within 5 to 15 minutes via cAMP-mediated relaxation of bronchial smooth muscle; they are the first-line treatment for acute bronchoconstriction. Levalbuterol is the R-enantiomer of albuterol; while it was proposed to have fewer cardiovascular side effects than racemic albuterol (the S-enantiomer was thought to be pharmacologically inactive), clinical evidence for meaningful benefit over racemic albuterol is limited. Long-acting beta-2 agonists (LABAs; salmeterol, formoterol, indacaterol, vilanterol) have durations of 12 to 24 hours and are used for maintenance therapy, always in combination with an inhaled corticosteroid (ICS) in asthma, to prevent exacerbations; LABA (long-acting beta-2 agonist) monotherapy without ICS is associated with increased asthma mortality and is contraindicated in asthma per current guidelines. Terbutaline given subcutaneously or intravenously can act as a uterine tocolytic (beta-2 AR relaxes uterine smooth muscle), used to briefly arrest preterm labor to allow administration of antenatal corticosteroids or transfer to a tertiary care facility; it is not approved for long-term tocolysis.7
Alpha-1 Agonists and Mixed Agents. Phenylephrine is a selective alpha-1 AR agonist that produces pure vasoconstriction without significant cardiac beta-1 stimulation, making it useful for hypotension during spinal anesthesia (where vasodilation predominates without cardiac dysfunction) and for nasal decongestion (topical vasoconstriction of nasal mucosal vessels). Its lack of beta-1 effect means it does not increase heart rate; instead, reflex bradycardia from baroreceptor activation may occur, which can be therapeutically useful in patients with supraventricular tachycardia (SVT) triggered by hypotension. Pseudoephedrine and phenylpropanolamine are oral alpha-1 agonists used for nasal decongestion; phenylpropanolamine was withdrawn due to increased hemorrhagic stroke risk. Ephedrine is a mixed direct and indirect sympathomimetic with both alpha-1 and beta-1 activity plus indirect NE release; it crosses the blood-brain barrier (BBB), produces central nervous system (CNS) stimulation, is absorbed orally, and has a longer duration than catecholamines. Midodrine is a prodrug converted to the active alpha-1 agonist desglymidodrine; used orally to treat orthostatic hypotension in dysautonomia, it selectively raises blood pressure in the standing position without cardiac stimulation.1014
Septic/distributive shock (vasodilation, low SVR, adequate or high cardiac output): NE first-line (alpha-1 vasoconstriction + beta-1 inotropic support). Add vasopressin (V1 receptor, non-adrenergic vasoconstriction) if NE dose escalating. Phenylephrine if tachyarrhythmia limits NE. Cardiogenic shock (low cardiac output, high SVR): dobutamine (beta-1 inotrope, reduces SVR via beta-2). Add NE if concomitant vasodilation. Mechanical support (IABP, Impella) preferred when pharmacological inotropes are insufficient. Anaphylaxis: epinephrine IM (alpha-1 + beta-1 + beta-2) is the only agent addressing all three pathophysiological mechanisms (laryngeal edema, hypotension, bronchoconstriction) simultaneously. Bradycardia/cardiac arrest: epinephrine IV in cardiac arrest; atropine for bradycardia; isoproterenol as temporizing bridge to pacing in refractory bradycardia.
Adrenergic antagonists (sympatholytics) block the postsynaptic effects of norepinephrine (NE) and epinephrine at alpha or beta adrenergic receptors (ARs). They encompass some of the most widely prescribed drug classes in medicine: beta-blockers for heart failure, hypertension, angina, and arrhythmias; alpha-1 blockers for hypertension and benign prostatic hyperplasia (BPH); and combined alpha-beta blockers for heart failure and hypertensive emergencies. Their clinical pharmacology follows directly from the receptor subtypes they block and the baseline sympathetic tone of the target tissues.
Alpha-1 Antagonists: Prazosin, Terazosin, Doxazosin, and Tamsulosin. Selective alpha-1 adrenergic receptor (AR) antagonists produce vasodilation (blocking sympathetically maintained vascular smooth muscle tone) and relax urethral sphincter and prostate smooth muscle. Prazosin was the first selective alpha-1 blocker and is pharmacologically important as a short-acting oral antihypertensive with a characteristic first-dose phenomenon: profound orthostatic hypotension and syncope after the initial dose due to vasodilation in a volume-dependent upright posture, because the reflex tachycardia that normally compensates for vasodilation is blunted by the alpha-1 blockade of venous capacitance vessels, reducing venous return. Prazosin is started at low dose at bedtime to reduce first-dose syncope risk. Terazosin and doxazosin are longer-acting analogs with similar profiles; doxazosin extended release is used for BPH with less hypotension. Tamsulosin and silodosin are selective for the alpha-1A subtype predominantly expressed in the prostate and bladder neck smooth muscle (versus the alpha-1B subtype dominant in vascular smooth muscle), producing urinary symptom relief with substantially less hypotension than non-selective alpha-1 blockers. Phentolamine is a non-selective short-acting alpha-blocker (blocks alpha-1 and alpha-2) useful for hypertensive emergencies from catecholamine excess (pheochromocytoma), cocaine-induced coronary vasospasm (where alpha-1 blockade reverses vasoconstriction), and local treatment of extravasation injuries from vasopressor infusions.1011
Beta-Blockers: Selectivity, Generation, and Clinical Applications. Beta-blockers are classified by their receptor selectivity and additional pharmacological properties. First-generation agents (propranolol, timolol, nadolol) are non-selective beta-1 and beta-2 blockers; their beta-2 blockade in airways makes them contraindicated in asthma and significantly risky in chronic obstructive pulmonary disease (COPD). Second-generation agents (metoprolol, atenolol, bisoprolol, esmolol) are cardioselective (preferentially block beta-1 over beta-2 at therapeutic doses), reducing bronchospasm risk while providing cardiac benefits; selectivity is dose-dependent and not absolute at higher doses. Third-generation agents add vasodilatory properties: carvedilol (non-selective beta plus alpha-1 blocker; vasodilation from alpha-1 blockade; also a potent antioxidant) and labetalol (non-selective beta plus alpha-1 blocker; alpha-to-beta blockade ratio approximately 1:7 oral, 1:3 IV) are used in heart failure and hypertension including hypertensive emergencies (labetalol IV). Nebivolol produces beta-1 blockade plus vasodilation through stimulation of endothelial nitric oxide (NO) release via a beta-3 AR or L-arginine pathway. Beta-blockers with intrinsic sympathomimetic activity, or ISA (partial beta-AR agonist property; acebutolol, pindolol) act as partial agonists at beta-ARs, causing less resting bradycardia and fewer metabolic effects but providing less morbidity-mortality benefit in post-MI and heart failure settings and are not preferred in those conditions.1213
Beta-Blocker Clinical Applications and Contraindications. Heart failure with reduced ejection fraction (HFrEF): carvedilol, metoprolol succinate, and bisoprolol reduce all-cause mortality and hospitalizations in stable HFrEF, an effect established in landmark randomized trials. The benefit is attributed to reversal of chronic sympathetic overstimulation-induced beta-1 AR downregulation, reduced cardiac remodeling, antiarrhythmic effects, and slowed heart rate allowing greater diastolic filling time. Beta-blockers must be initiated in stable, euvolemic HFrEF patients and are not used in acutely decompensated heart failure. Hypertension: reduce heart rate and cardiac output; also reduce renin release by blocking beta-1 ARs in the juxtaglomerular apparatus, lowering angiotensin II. Angina: reduce myocardial oxygen demand by decreasing heart rate, contractility, and systolic wall stress. Acute MI: reduce infarct extension and mortality after acute myocardial infarction (MI); metoprolol IV followed by oral reduces sympathetically driven ventricular arrhythmias. Arrhythmias: suppress sinoatrial (SA) node automaticity and slow atrioventricular (AV) conduction (rate control in atrial fibrillation); esmolol useful for perioperative tachyarrhythmias. Absolute contraindications: severe asthma; high-degree AV block (second-degree Mobitz type II or third-degree) without pacing; acute decompensated heart failure with low output. Relative contraindications: reactive airway disease (use selective beta-1 with caution); diabetes (may blunt hypoglycemic symptoms and prolong hypoglycemia).1213
Abrupt discontinuation of beta-blockers after chronic use exposes upregulated beta-ARs (a consequence of chronic receptor blockade; see Module 3) to endogenous catecholamines, producing rebound tachycardia, hypertension, angina exacerbation, and in patients with ischemic heart disease, potentially precipitating myocardial infarction (MI). The clinical risk is highest in patients with underlying CAD. Management: taper beta-blocker dose gradually over 1 to 2 weeks in patients with stable ischemic heart disease; if abrupt discontinuation is unavoidable (e.g., surgery), ensure analgesia and anxiolysis to minimize catecholamine surges, and restart as soon as feasible. The same pharmacological principle applies to clonidine withdrawal (alpha-2 AR upregulation → rebound hypertension from disinhibition of NE release) and nitrate tolerance (upregulation of endothelin and vasoconstrictor pathways).
The response to an autonomic drug is not determined solely by the drug's receptor profile; it is shaped by the baseline autonomic tone of the target organ, the relative density and coupling efficiency of receptor subtypes, the influence of reflex compensatory mechanisms, and the pharmacological context created by other drugs the patient is taking. A systematic framework for predicting drug effects and interactions begins with the concept of dominant innervation and the resting sympathovagal balance.
Dominant Innervation and Resting Tone. Most organs receive dual autonomic innervation, but the relative dominance of sympathetic or parasympathetic input differs by tissue. The heart at rest is under dominant vagal (parasympathetic) tone: resting heart rate in a normally innervated individual at rest is approximately 70 beats per minute, but the intrinsic rate of the sinoatrial (SA) node pacemaker cells is approximately 100 beats per minute. This difference (approximately 30 beats per minute) represents continuous vagal suppression of the intrinsic rate; complete vagal blockade with atropine raises heart rate toward the intrinsic rate, demonstrating the magnitude of resting vagal tone. The peripheral vasculature is under dominant sympathetic tone: loss of sympathetic vasomotor input (from spinal cord injury, epidural anesthesia, ganglionic blockade, or alpha-blocker administration) produces profound vasodilation, reducing systemic vascular resistance (SVR) and blood pressure. The gastrointestinal (GI) tract is under dominant parasympathetic tone for motility and secretion; sympathetic activation (stress, pain, hemorrhage) reduces GI motility, while parasympathetic blockade (antimuscarinics) reduces it as well. The bladder at rest stores urine under sympathetic dominance (alpha-1 maintains sphincter tone; beta-3 relaxes detrusor); voiding is initiated by parasympathetic activation (M3 contracts detrusor). Understanding which division dominates each organ at rest allows prediction of the net effect of any autonomic drug or surgical anesthesia technique on that organ.1415
Baroreceptor Reflex as a Modifier of Drug Effects. The baroreceptor reflex (carotid sinus and aortic arch baroreceptors projecting to the nucleus tractus solitarius [NTS]) continuously adjusts heart rate and vasomotor tone in response to blood pressure changes. This reflex powerfully modifies the cardiovascular effects of autonomic drugs and must be accounted for in clinical predictions. Phenylephrine (alpha-1 agonist) raises blood pressure by increasing SVR; the baroreceptor reflex responds by increasing vagal outflow and reducing sympathetic tone to the SA node, producing reflex bradycardia. The magnitude of reflex bradycardia can be clinically useful: in supraventricular tachycardia (SVT) associated with hypotension, phenylephrine raises blood pressure and thereby provokes reflex vagal stimulation that may terminate the arrhythmia, analogous to the Valsalva maneuver. Beta-blockers reduce heart rate and contractility, lowering mean arterial pressure (MAP); the baroreceptor reflex would normally compensate with increased sympathetic tone and tachycardia, but beta-1 blockade prevents heart rate from rising, so the compensatory response is attenuated, explaining the persistent bradycardia and reduced heart rate variability on chronic beta-blocker therapy.
Vasodilators (hydralazine, dihydropyridine calcium channel blockers) lower MAP and trigger reflex tachycardia through baroreceptor-mediated sympathetic activation; combining them with beta-blockers blunts this reflex tachycardia, which is one reason that combination therapy is frequently employed. Awareness of the baroreceptor reflex is essential for understanding why the hemodynamic effects of autonomic drugs in awake, intact patients differ from effects measured in isolated organ preparations or anesthetized animals.1415
Predicting Pharmacodynamic Drug Interactions. Autonomic drug interactions can be categorized as additive, synergistic, or antagonistic based on the receptor mechanisms involved. Additive interactions occur when two drugs act at the same receptor to produce the same effect: atropine plus glycopyrrolate both block muscarinic receptors, and their anticholinergic effects add. Synergistic interactions exceed simple addition: the combination of a norepinephrine (NE) reuptake inhibitor (TCA or SNRI) with a monoamine oxidase inhibitor (MAOI) produces explosive monoamine accumulation at adrenergic synapses because the reuptake mechanism and the degradation pathway are simultaneously disabled, and the resulting NE excess exceeds what blockade of either pathway alone would produce. Antagonistic interactions reduce efficacy: a beta-2 agonist for asthma (albuterol) and a non-selective beta-blocker (propranolol) act at the same receptor with opposing effects; the beta-blocker reduces the therapeutic bronchodilatory effect of albuterol while the albuterol at high concentrations competes with propranolol at the receptor.
Pharmacokinetic interactions are distinct from pharmacodynamic ones but may amplify autonomic drug effects: cytochrome P450 2D6 (CYP2D6) inhibitors (fluoxetine, paroxetine, bupropion) substantially increase plasma levels of metoprolol (a CYP2D6 substrate), producing unexpectedly severe bradycardia and heart block at standard metoprolol doses; dose reduction may be required. Understanding the mechanism type of each interaction allows the clinician to predict both the direction and the approximate magnitude of the interaction rather than relying on memorized lists.1516
Autonomic Effects of Non-Autonomic Drugs. Many drugs that are not primarily classified as autonomic agents produce significant autonomic effects that must be recognized in clinical practice. Tricyclic antidepressants (TCAs) block the norepinephrine transporter (NET), the serotonin transporter (SERT), and muscarinic receptors, producing anticholinergic effects (tachycardia, urinary retention, constipation, dry mouth) plus orthostatic hypotension from alpha-1 blockade, and cardiac conduction abnormalities from sodium channel blockade. Antipsychotics (particularly first-generation typical agents such as haloperidol, chlorpromazine, and thioridazine) block alpha-1 and muscarinic receptors in addition to their dopamine D2 (D2) receptor effects, producing orthostatic hypotension and anticholinergic effects. Opioids release histamine (particularly morphine and meperidine) and reduce sympathetic tone through central nervous system (CNS) mechanisms, producing hypotension; fentanyl produces less histamine release and less hypotension, explaining its preference in hemodynamically unstable patients. General anesthetics reduce sympathetic tone and vascular resistance, requiring understanding of baseline autonomic pharmacology to manage intraoperative hemodynamics. Fluoroquinolone antibiotics, macrolides, and antifungals that inhibit cytochrome P450 3A4 (CYP3A4) may increase plasma levels of autonomic drugs metabolized by this enzyme, creating pharmacokinetic-pharmacodynamic interactions.151617
Heart: vagal dominant → atropine/ganglionic blockade → tachycardia. Blood vessels: sympathetic dominant → alpha-blockers/ganglionic blockade → vasodilation + orthostatic hypotension. GI tract: parasympathetic dominant → antimuscarinics → reduced motility (constipation, ileus). Bladder detrusor: parasympathetic dominant → antimuscarinics → urinary retention; M3 agonists/AChEIs → detrusor contraction, voiding. Urethral sphincter: sympathetic dominant (alpha-1) → alpha-1 blockers → improved flow (BPH). Salivary glands: parasympathetic dominant → antimuscarinics → dry mouth; M3 agonists (pilocarpine, cevimeline) → increased secretion (Sjögren, xerostomia). Eye pupil: parasympathetic dominant → antimuscarinics → mydriasis; alpha-1 agonists → mydriasis (dilator muscle). Sweat glands: sympathetic cholinergic (M3) → antimuscarinics → anhidrosis; hyperthermia risk.
The preceding three modules have established the foundational mechanisms of autonomic neurotransmission, receptor pharmacology, and drug class properties. This final section applies that framework to clinical scenarios that require integration of multiple concepts. Each scenario illustrates a core principle of autonomic pharmacology that recurs in clinical practice and in pharmacology examinations.
Scenario 1: Organophosphate Pesticide Poisoning. A 42-year-old agricultural worker presents with profuse salivation, lacrimation, urinary incontinence, severe diarrhea, abdominal cramping, bradycardia, bronchospasm with wheezing, and miosis. He is confused and seizing. The mechanism is irreversible AChE inhibition → accumulation of ACh at all cholinergic synapses: muscarinic excess produces SLUDGE (salivation, lacrimation, urination, defecation, GI cramping, emesis) plus bradycardia, bronchospasm, and miosis; nicotinic excess at the neuromuscular junction (NMJ) produces fasciculations and then flaccid paralysis; nicotinic excess at ganglia produces complex ganglionic effects; central nervous system (CNS) excess produces seizures, coma, and respiratory failure. Treatment: secure airway (paralysis and hypersecretion risk); atropine titrated to drying of secretions (not heart rate; 2 to 4 mg IV every 5 to 10 min, titrating to reduced bronchial secretions; total dose may exceed 20 to 30 mg in severe cases); pralidoxime (2-PAM) IV to reactivate AChE before irreversible aging (most effective within 24 to 48 hours of exposure); benzodiazepines for seizures; ventilatory support for respiratory failure from NMJ paralysis. Understanding that atropine treats muscarinic but not nicotinic toxicity, and that 2-PAM addresses the underlying mechanism, is essential for competent management.1
Scenario 2: Pheochromocytoma Preoperative Management. A 38-year-old woman with episodic hypertensive crises (pressures up to 240/130 mmHg), diaphoresis, headache, and palpitations is found to have elevated plasma free metanephrines and a 4 cm right adrenal mass on imaging consistent with pheochromocytoma (PHEO). The autonomic pharmacology of PHEO management illustrates several key principles: (1) alpha-blockade must be established first, for a minimum of 10 to 14 days preoperatively, to allow volume expansion in the chronically vasoconstricted state; phenoxybenzamine (irreversible alpha-1 plus alpha-2 blocker) is the traditional agent; selective alpha-1 blockers (doxazosin, prazosin) are increasingly used with equivalent perioperative outcomes; (2) beta-blockade is added only after adequate alpha-blockade to control reflex tachycardia; starting a beta-blocker before alpha-blockade is contraindicated because blockade of beta-2 vasodilation removes a compensatory mechanism and allows unopposed alpha-1 vasoconstriction to produce a hypertensive crisis; (3) intraoperative catecholamine surges during tumor manipulation are managed with phentolamine (short-acting, titratable) or sodium nitroprusside IV; (4) norepinephrine (NE) infusion postoperatively may be required when tumor removal abruptly eliminates the excess catecholamine source and the chronically downregulated adrenergic receptors in the peripheral vasculature cannot respond adequately to normal sympathetic tone, producing hypotension.11
Scenario 3: Asthma Exacerbation in a Patient on a Beta-Blocker. A 55-year-old with hypertension maintained on metoprolol succinate 100 mg daily develops an acute asthma exacerbation. The pharmacological tension: metoprolol is a cardioselective beta-1 blocker, but at 100 mg daily, beta-1 selectivity is not absolute, and some beta-2 blockade in the airways may be present, contributing to increased bronchial smooth muscle tone and reducing the bronchodilatory response to albuterol. Management options illustrate the principle of receptor competition: ipratropium (muscarinic M3 [M3] antagonist, non-adrenergic bronchodilation) provides bronchodilation through a receptor system not affected by beta-blockade and should be added early. Albuterol doses may need to be higher to overcome partial competitive beta-2 blockade; the salbutamol/ipratropium combination is more effective than either alone. If beta-blocker discontinuation is necessary, the drug should not be abruptly stopped (risk of rebound angina or tachycardia if underlying ischemic heart disease); transition to a selective beta-1 blocker if continued cardiac indication exists. This scenario underscores why the indication for a non-selective beta-blocker in a patient with reactive airway disease must be absolutely compelling, as no truly safe option exists.912
Scenario 4: Anesthesia for a Patient on Chronic Alpha-2 Agonist Therapy. A 67-year-old with hypertension controlled on clonidine 0.2 mg twice daily is scheduled for elective surgery. The anesthetic implications: clonidine (central alpha-2A agonist) reduces sympathetic outflow, lowering heart rate and blood pressure at baseline; abrupt discontinuation before surgery can precipitate rebound hypertension (disinhibition of NE release from upregulated alpha-2 presynaptic autoreceptors). Plan: continue clonidine through the morning of surgery with a sip of water; if the patient cannot take oral medications perioperatively, use a transdermal clonidine patch started 24 hours before surgery to maintain steady-state levels. Intraoperative implications: the patient may be more sensitive to hypotension from anesthetic-induced vasodilation because of reduced baseline sympathetic tone; vasopressor requirements may differ from patients not on central sympatholytics; the bradycardia produced by some anesthetic agents (propofol, opioids) may be additive with clonidine-induced bradycardia. These considerations require preoperative communication between the prescribing physician and the anesthesia team, illustrating the importance of autonomic pharmacology literacy across disciplines.1415
Module 1 established ANS anatomy: the two-neuron arc, sympathetic (thoracolumbar, short preganglionic, long postganglionic, adrenal medulla) versus parasympathetic (craniosacral, long preganglionic, short postganglionic), and the enteric nervous system as the third division. Module 2 covered neurotransmitter synthesis, vesicular storage, calcium-triggered exocytosis, and signal termination (AChE/BuChE hydrolysis; NET reuptake, MAO, and COMT degradation), with drug targets at every step. Module 3 mapped each receptor subtype (muscarinic M1–M5, nicotinic NM and NN, adrenergic alpha-1/2 and beta-1/2/3, dopamine D1–D5) to its G-protein coupling, second messenger cascade, tissue distribution, and selective drug targets, concluding with receptor regulation and the clinical prediction framework. This final module translated all preceding knowledge into drug class pharmacology and integrated clinical application. Together, these four modules provide the mechanistic foundation for all subsequent ANS-related pharmacology encountered in the cardiovascular, pulmonary, renal, gastrointestinal, and neurological drug chapters of this curriculum.
Taylor P. Anticholinesterase agents. In: Brunton LL, Hilal-Dandan R, Knollmann BC, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 13th ed. New York: McGraw-Hill; 2018:163-186.
Westfall TC, Westfall DP. Adrenergic agonists and antagonists. In: Brunton LL, Hilal-Dandan R, Knollmann BC, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 13th ed. New York: McGraw-Hill; 2018:187-226.
Greig NH, Lahiri DK, Sambamurti K. Butyrylcholinesterase: an important new target in Alzheimer's disease therapy. Int Psychogeriatr. 2002;14(Suppl 1):77-91.
doi:10.1017/S1041610203008676Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet. 2016;387(10037):2507-2520.
doi:10.1016/S0140-6736(16)30272-0Brown JH, Laiken N. Muscarinic receptor agonists and antagonists. In: Brunton LL, Hilal-Dandan R, Knollmann BC, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 13th ed. New York: McGraw-Hill; 2018:149-162.
Westfall TC, Westfall DP. Neurotransmission: the autonomic and somatic motor nervous systems. In: Brunton LL, Hilal-Dandan R, Knollmann BC, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 13th ed. New York: McGraw-Hill; 2018:101-147.
Overgaard CB, Dzavik V. Inotropes and vasopressors: review of physiology and clinical use in cardiovascular disease. Circulation. 2008;118(10):1047-1056.
doi:10.1161/CIRCULATIONAHA.107.728840De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010;362(9):779-789.
doi:10.1056/NEJMoa0907118Bateman ED, Reddel HK, O'Byrne PM, et al. As-needed budesonide-formoterol versus maintenance budesonide in mild asthma. N Engl J Med. 2018;378(20):1877-1887.
doi:10.1056/NEJMoa1715275Sica DA, Gehr TWB. Alpha-1-adrenergic blockers. In: Black HR, Elliott WJ, eds. Hypertension: A Companion to Braunwald's Heart Disease. 2nd ed. Philadelphia: Saunders; 2013:199-210.
Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2014;99(6):1915-1942.
doi:10.1210/jc.2014-1498Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37(27):2129-2200.
doi:10.1093/eurheartj/ehw128Frishman WH. Carvedilol. N Engl J Med. 1998;339(24):1759-1765.
doi:10.1056/NEJM199812103392407Katzung BG, ed. Basic and Clinical Pharmacology. 15th ed. New York: McGraw-Hill; 2021.
Aronson JK, ed. Meyler's Side Effects of Drugs. 16th ed. Amsterdam: Elsevier; 2016.
Flockhart DA. Drug interactions: cytochrome P450 drug interaction table. Indiana University School of Medicine. 2007. Available at: https://drug-interactions.medicine.iu.edu
Eisenhofer G, Kopin IJ, Goldstein DS. Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev. 2004;56(3):331-349.
doi:10.1124/pr.56.3.1